Please login to the form below

Not currently logged in
Email:
Password:

PPRS changes delayed

The Department of Health has postponed the date on which pharmaceutical companies will be required to reduce the price of its non-exclusive medicines

The Department of Health has postponed the date on which pharmaceutical companies will be required to reduce the price of its non-exclusive medicines.

The new Pharmaceutical Price Regulation Scheme (PPRS), a joint initiative from the Department of Health (DH) and the Association of the British Pharmaceutical Industry (ABPI), was due to take effect from January 1, 2009.

A key part of this new scheme is a requirement for pharmaceutical companies to reduce the price of their branded medicines once they are off-patent to bring them more inline with the price of generic equivalents. The DH has since decided that a public consultation is required, which will delay the launch of the scheme by at least three months.

This change is likely to cause uncertainty for pharmaceutical companies after they agreed a deal earlier this year to reduce prices of branded generic drugs to 1.5 times the reimbursement rate for generics. Any change to this rate will also have a negative impact on manufacturers of generic medicines.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics